Daichi Hoshina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daichi Hoshina has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
K. Furuya
Department of Dermatology, Hakodate Central General Hospital, Honcho 33-2, Hakodate, 040-8585, Japan
3 shared publicationsKazuhiko Furuya
Department of Dermatology, Hakodate Central General Hospital, Hakodate, Japan
3 shared publications- Akihiro Orita
Department of Dermatology Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
2 shared publications Masumi Tsujiwaki
Department of Dermatology, Hakodate Central General Hospital, Hakodate, Japan
2 shared publications- Riichiro Abe
Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences
2 shared publications Ayame Kimura
Department of Dermatology Otaru General Hospital Otaru Japan
1 shared publication
Latest Publications
- 14 May 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (11) , 1610-1611
Cutaneous T‐cell pseudolymphoma successfully treated with topical delgocitinib
- 14 May 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (11) , 1610-1611
Cutaneous T‐cell pseudolymphoma successfully treated with topical delgocitinib
- 7 March 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (3) , e77-e78
Mycosis fungoides‐like eruptions associated with abatacept
- 7 March 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (3) , e77-e78
Mycosis fungoides‐like eruptions associated with abatacept
- Open Access
- 31 October 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (12) , e15948
Intravenous immunoglobulin for pembrolizumab‐induced bullous pemphigoid‐like eruption: A case report
- 31 October 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (12) , e15948
Open AccessIntravenous immunoglobulin for pembrolizumab‐induced bullous pemphigoid‐like eruption: A case report
- 22 April 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (7) , 1372-1374
Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review
We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.
- 22 April 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (7) , 1372-1374
Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review
We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.
- Open Access
- 17 January 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (5) , 175-176
Sweet syndrome after severe acute respiratory syndrome coronavirus 2 mRNA vaccine: A case report and literature review
- 17 January 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (5) , 175-176
Open AccessSweet syndrome after severe acute respiratory syndrome coronavirus 2 mRNA vaccine: A case report and literature review
- 3 March 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (10) , 2060-2072.e6
Inhibition of Endoglin Exerts Antitumor Effects through the Regulation of Non-Smad TGF-β Signaling in Angiosarcoma
- 3 March 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (10) , 2060-2072.e6
Inhibition of Endoglin Exerts Antitumor Effects through the Regulation of Non-Smad TGF-β Signaling in Angiosarcoma
- 10 September 2019
- Published by Morressier GmbH
Endoglin enhances the progression of angiosarcoma through the regulation of non-Smad TGF-β signaling
Angiosarcoma is a rare malignant tumor derived from endothelial cells and its prognosis is poor because advanced angiosarcoma is resistant to sta |
- 10 September 2019
- Published by Morressier GmbH
Endoglin enhances the progression of angiosarcoma through the regulation of non-Smad TGF-β signaling
Angiosarcoma is a rare malignant tumor derived from endothelial cells and its prognosis is poor because advanced angiosarcoma is resistant to sta |
- 4 January 2018
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (6) , 718-719
Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab
- 4 January 2018
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (6) , 718-719
Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab
- 18 December 2016
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (5) , e83-e84
Erythema multiforme associated with Trueperella pyogenes bacteremia
- 18 December 2016
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (5) , e83-e84
Erythema multiforme associated with Trueperella pyogenes bacteremia
- 12 December 2016
- Published by Wiley in Contact Dermatitis
- Vol. 76 (1) , 57-58
Onychomadesis caused by efinaconazole
- 12 December 2016
- Published by Wiley in Contact Dermatitis
- Vol. 76 (1) , 57-58
Onychomadesis caused by efinaconazole